Literature DB >> 25274033

Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.

Chuandong Geng1, Kimal Rajapakshe2, Shrijal S Shah1, John Shou1, Vijay Kumar Eedunuri3, Christopher Foley1, Warren Fiskus1, Mahitha Rajendran1, Sue Anne Chew1, Martin Zimmermann1, Richard Bond1, Bin He1, Cristian Coarfa4, Nicholas Mitsiades5.   

Abstract

Somatic missense mutations in the substrate-binding pocket of the E3 ubiquitin ligase adaptor SPOP are present in up to 15% of human prostate adenocarcinomas, but are rare in other malignancies, suggesting a prostate-specific mechanism of action. SPOP promotes ubiquitination and degradation of several protein substrates, including the androgen receptor (AR) coactivator SRC-3. However, the relative contributions that SPOP substrates may make to the pathophysiology of SPOP-mutant (mt) prostate adenocarcinomas are unknown. Using an unbiased bioinformatics approach, we determined that the gene expression profile of prostate adenocarcinoma cells engineered to express mt-SPOP overlaps greatly with the gene signature of both SRC-3 and AR transcriptional output, with a stronger similarity to AR than SRC-3. This finding suggests that in addition to its SRC-3-mediated effects, SPOP also exerts SRC-3-independent effects that are AR-mediated. Indeed, we found that wild-type (wt) but not prostate adenocarcinoma-associated mutants of SPOP promoted AR ubiquitination and degradation, acting directly through a SPOP-binding motif in the hinge region of AR. In support of these results, tumor xenografts composed of prostate adenocarcinoma cells expressing mt-SPOP exhibited higher AR protein levels and grew faster than tumors composed of prostate adenocarcinoma cells expressing wt-SPOP. Furthermore, genetic ablation of SPOP was sufficient to increase AR protein levels in mouse prostate. Examination of public human prostate adenocarcinoma datasets confirmed a strong link between transcriptomic profiles of mt-SPOP and AR. Overall, our studies highlight the AR axis as the key transcriptional output of SPOP in prostate adenocarcinoma and provide an explanation for the prostate-specific tumor suppressor role of wt-SPOP. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25274033      PMCID: PMC4209379          DOI: 10.1158/0008-5472.CAN-14-0476

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

1.  ARN-509: a novel antiandrogen for prostate cancer treatment.

Authors:  Nicola J Clegg; John Wongvipat; James D Joseph; Chris Tran; Samedy Ouk; Anna Dilhas; Yu Chen; Kate Grillot; Eric D Bischoff; Ling Cai; Anna Aparicio; Steven Dorow; Vivek Arora; Gang Shao; Jing Qian; Hong Zhao; Guangbin Yang; Chunyan Cao; John Sensintaffar; Teresa Wasielewska; Mark R Herbert; Celine Bonnefous; Beatrice Darimont; Howard I Scher; Peter Smith-Jones; Mark Klang; Nicholas D Smith; Elisa De Stanchina; Nian Wu; Ouathek Ouerfelli; Peter J Rix; Richard A Heyman; Michael E Jung; Charles L Sawyers; Jeffrey H Hager
Journal:  Cancer Res       Date:  2012-01-20       Impact factor: 12.701

2.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

Authors:  Changmeng Cai; Sen Chen; Patrick Ng; Glenn J Bubley; Peter S Nelson; Elahe A Mostaghel; Brett Marck; Alvin M Matsumoto; Nicholas I Simon; Hongyun Wang; Shaoyong Chen; Steven P Balk
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

3.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.

Authors:  Christopher E Barbieri; Sylvan C Baca; Michael S Lawrence; Francesca Demichelis; Mirjam Blattner; Jean-Philippe Theurillat; Thomas A White; Petar Stojanov; Eliezer Van Allen; Nicolas Stransky; Elizabeth Nickerson; Sung-Suk Chae; Gunther Boysen; Daniel Auclair; Robert C Onofrio; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Karen Sheikh; Terry Vuong; Candace Guiducci; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Wasay M Hussain; Alex H Ramos; Wendy Winckler; Michelle C Redman; Kristin Ardlie; Ashutosh K Tewari; Juan Miguel Mosquera; Niels Rupp; Peter J Wild; Holger Moch; Colm Morrissey; Peter S Nelson; Philip W Kantoff; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nat Genet       Date:  2012-05-20       Impact factor: 38.330

4.  Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

Authors:  Nicholas Mitsiades; Clifford C Sung; Nikolaus Schultz; Daniel C Danila; Bin He; Vijay Kumar Eedunuri; Martin Fleisher; Chris Sander; Charles L Sawyers; Howard I Scher
Journal:  Cancer Res       Date:  2012-09-12       Impact factor: 12.701

5.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Authors:  Rong Hu; Changxue Lu; Elahe A Mostaghel; Srinivasan Yegnasubramanian; Meltem Gurel; Clare Tannahill; Joanne Edwards; William B Isaacs; Peter S Nelson; Eric Bluemn; Stephen R Plymate; Jun Luo
Journal:  Cancer Res       Date:  2012-06-18       Impact factor: 12.701

6.  The androgen receptor gene mutations database: 2012 update.

Authors:  Bruce Gottlieb; Lenore K Beitel; Abbesha Nadarajah; Miltiadis Paliouras; Mark Trifiro
Journal:  Hum Mutat       Date:  2012-03-13       Impact factor: 4.878

7.  Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.

Authors:  Yingming Li; Majid Alsagabi; Danhua Fan; G Steven Bova; Ahmed H Tewfik; Scott M Dehm
Journal:  Cancer Res       Date:  2011-01-19       Impact factor: 12.701

8.  Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression.

Authors:  Jun Yan; Halime Erdem; Rile Li; Yi Cai; Gustavo Ayala; Michael Ittmann; Li-yuan Yu-Lee; Sophia Y Tsai; Ming-Jer Tsai
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

9.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Authors:  Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

10.  Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1.

Authors:  C Li; J Ao; J Fu; D-F Lee; J Xu; D Lonard; B W O'Malley
Journal:  Oncogene       Date:  2011-05-16       Impact factor: 9.867

View more
  73 in total

1.  Comprehensive proteomic profiling identifies the androgen receptor axis and other signaling pathways as targets of microRNAs suppressed in metastatic prostate cancer.

Authors:  C Coarfa; W Fiskus; V K Eedunuri; K Rajapakshe; C Foley; S A Chew; S S Shah; C Geng; J Shou; J S Mohamed; B W O'Malley; N Mitsiades
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

Review 2.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

Review 3.  Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.

Authors:  Christopher Foley; Nicholas Mitsiades
Journal:  Horm Cancer       Date:  2016-01-04       Impact factor: 3.869

Review 4.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

Review 5.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 6.  Implications of ubiquitin ligases in castration-resistant prostate cancer.

Authors:  Jianfei Qi; Lingling Fan; Arif Hussain
Journal:  Curr Opin Oncol       Date:  2015-05       Impact factor: 3.645

Review 7.  Functional analysis of Cullin 3 E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Zhiwei Wang; Brian J North; Kaixiong Tao; Xiangpeng Dai; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-08       Impact factor: 10.680

8.  Uterine function in the mouse requires speckle-type poz protein.

Authors:  Lan Hai; Maria M Szwarc; Bin He; David M Lonard; Ramakrishna Kommagani; Francesco J DeMayo; John P Lydon
Journal:  Biol Reprod       Date:  2018-06-01       Impact factor: 4.285

Review 9.  Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.

Authors:  Mark Daniel; Scott M Dehm
Journal:  J Steroid Biochem Mol Biol       Date:  2016-04-28       Impact factor: 4.292

Review 10.  SPOP and cancer: a systematic review.

Authors:  Alison Clark; Marieke Burleson
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.